Author

Jingjing Jiang

Revolution Medicines (United States)ORCID 0000-0003-0732-334XUnclaimed ORCID profile · follow to get notified of new preprints

Additional preprints under this name without ORCID

Jingjing Jiang2 papers · Chinese Academy of Sciences

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:human· 1 Organism:mouse· 1 Research Focus:perturbation response prediction· 1

Frequent Co-Authors

A. Cole EdwardsiD· 1 shared Álvaro Curiel‐GarcíaiD· 1 shared Amanda R. Decker-FarrelliD· 1 shared Amber M. AmparoiD· 1 shared Andrea CalifanoiD· 1 shared Andrew J. AguirreiD· 1 shared Basil S. Bakir· 1 shared Ben Z. StangeriD· 1 shared

Activity by Year

2024-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. Cole EdwardsORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Cancer BiologyNaturePeer-reviewedApr 8, 2024

Tumor-selective effects of active RAS inhibition in pancreatic ductal adenocarcinoma

Urszula N. Wasko, Jingjing Jiang, Tanner C. Dalton…·Kenneth P. Olive

This study evaluates the therapeutic potential of RMC-7977, a broad-spectrum RAS inhibitor, in pancreatic ductal adenocarcinoma models, showing strong anti-tumor effects with minimal impact on normal tissues.

225 citationstop 1%

𝕏 PostBluesky